PUBLISHER: Grand View Research | PRODUCT CODE: 1587802
PUBLISHER: Grand View Research | PRODUCT CODE: 1587802
The global ADME toxicology testing market size is expected to reach USD 11.44 billion by 2030, expanding at a CAGR of 10.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Factors such as increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies are expected to aid revenue generation for the market.
Absorption, distribution, metabolism, and excretion (ADME) toxicology testing is used to test toxic reactions caused by molecules in clinical trials on factors and systemic reactions such as chemical, pharmaceutical, and genetic. These toxicology testing procedures help in effective drug development, which limits or prevents toxic reactions to the body when administered. Toxicity levels are decided on the results of a series of tests conducted in near-natural conditions, which represent almost real-time reactions between the drug and the host.
As of 2017, approximately 43.0% of ADME toxicology testing areas carried out are based on cell culture tech. Cell culture technology is adopted widely owing to advantages such as near-natural conditions and accurate results obtained at a cellular level.
These assays are conducted for several types of toxic reactions or systems where toxic reactions might take place. Some of the toxicity tests are systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and other toxicities that might result in living tissue. Advancements in testing methods are underway and this trend is likely to be picked up by many companies developing drug molecules. This will speed up the drug discovery process and boost the market growth.